SynAct Pharma Aps   Report issue

For profit Phase 2
Founded: Lund Sweden (2012)

Organization Overview

First Clinical Trial
2019
NCT04004429
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

SynAct Pharma Aps

Active Ingredients

Drugs in Phase 2 Trials (1)

resomelagon (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 2)

Arthritis, Rheumatoid (Phase 2)

Glomerulonephritis, Membranous (Phase 2)

Joint Diseases (Phase 2)

Kidney Diseases (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 1